Leman Biotech has developed a novel CAR-T cell therapy that utilizes a significantly lower dosage, just 1‰ of the conventional amount, while achieving remarkable efficacy. This approach, which involves metabolically enhancing T cells using IL-10 to reverse exhaustion, has demonstrated a 100% complete remission rate in early clinical studies for patients with relapsed or refractory blood cancers. The reduced dosage not only improves safety and shortens production cycles but also drastically cuts manufacturing costs, potentially making CAR-T therapy more accessible. AI
IMPACT This breakthrough in CAR-T therapy could significantly lower treatment costs and improve patient outcomes, potentially accelerating the adoption of advanced cell therapies.
RANK_REASON The article details a novel CAR-T therapy from Leman Biotech, a company founded by a professor from EPFL, which demonstrates a significant improvement in efficacy and cost-effectiveness through a unique metabolic enhancement mechanism. [lever_c_demoted from frontier_release: ic=1 ai=0.7]
- CAR-T cell therapy
- JAMA Oncology
- Lancet Haematology
- META 10-19
- MP-5342
- Nature
- Nature Biotechnology
- Nature Immunology
- Prix Galien USA
- SIGX1094
- United States Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
